NCORP Specific COVID-19 Guidance Listed
Last Updated: April 22, 2020
Federal guidance related to the coronavirus (COVID-19) that may be useful to the NCI Community Oncology Research Program (NCORP) is listed below, in addition to the links provided in the banner headline. As new guidance is made available this list will be updated.
Guidance for All Researchers
- Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
- Get the latest research information from the National Institutes of Health (NIH): https://covid19.nih.gov/
Guidance Specific to the Conduct of Clinical Trials
- NCI Central Institutional Review Board (CIRB) Guidance for the New Coronavirus https://www.ncicirb.org/ April 22, 2020
- Memorandum on Guidance for Collection of Adverse Events Related to COVID-19 Infection (PDF) March 25, 2020
- Memorandum on Additional Guidance for Clinical Trial Activities Affected by the Novel Coronavirus (PDF, 149 KB) March 23, 2020
- Interim Guidance for Patients on Clinical Trials Supported by the NCI CTEP and NCORP (PDF, 210 KB) March 13, 2020
- FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic Guidance for Industry, Investigators, and Institutional Review Boards, Released March 18, 2020, Updated March 27, 2020 (PDF)